MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Stryker Corp

Slēgts

SektorsVeselības aprūpe

360.88 0.87

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

353.66

Max

361.08

Galvenie mērījumi

By Trading Economics

Ienākumi

-288M

546M

Pārdošana

946M

6.4B

P/E

Sektora vidējais

43.649

57.333

EPS

4.01

Dividenžu ienesīgums

0.99

Peļņas marža

8.484

Darbinieki

53,000

EBITDA

385M

1.8B

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+20.25% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.99%

2.63%

Nākamie ieņēmumi

2025. g. 1. maijs

Nākamais dividenžu datums

2025. g. 30. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-18B

132B

Iepriekšējā atvēršanas cena

360.01

Iepriekšējā slēgšanas cena

360.88

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

Stryker Corp Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 28. janv. 21:55 UTC

Peļņas

Stryker Sees Further Organic Sales Growth in 2025

2025. g. 28. janv. 21:46 UTC

Iegādes, apvienošanās, pārņemšana

Stryker to Sell Spinal Implants Business to Viscogliosi Brothers

2025. g. 6. janv. 22:18 UTC

Iegādes, apvienošanās, pārņemšana

Stryker to Acquire Inari Medical in Deal Valued at $4.9 Billion -- Update

2025. g. 6. janv. 21:39 UTC

Iegādes, apvienošanās, pārņemšana

Stryker to Acquire Inari Medical in Deal Valued at $4.9 Billion

2025. g. 19. febr. 13:53 UTC

Iegādes, apvienošanās, pārņemšana

Stryker Files 8K - Asset Acquisition Or Disposition >SYK

2025. g. 19. febr. 13:30 UTC

Iegādes, apvienošanās, pārņemšana

Stryker Completes Acquisition Of Inari Medical, Inc., Providing Entry Into The High-growth Peripheral Vascular Segment >SYK

2025. g. 28. janv. 21:09 UTC

Iegādes, apvienošanās, pārņemšana

Stryker: Transaction Is Expected to Close in the U.S. in 1H 2025 >SYK

2025. g. 28. janv. 21:09 UTC

Iegādes, apvienošanās, pārņemšana

Stryker: Agreement Includes Binding Offer to Acquire Stryker's Spinal Implants Business in France >SYK

2025. g. 28. janv. 21:08 UTC

Iegādes, apvienošanās, pārņemšana

Stryker: After Closing, VB Spine Will Become a Strategic Partner to Stryker With Exclusive Access to Mako Spine and Copilot for Use With VB Spine's Implants in Spine Procedures >SYK

2025. g. 28. janv. 21:08 UTC

Iegādes, apvienošanās, pārņemšana

Stryker: Agreement to Sell U.S. Spinal Implants Business to Viscogliosi Brothers, LLC to Create Newly Formed Co Called VB Spine, LLC >SYK

2025. g. 28. janv. 21:06 UTC

Peļņas

Stryker Sees Organic Net Sales Growth of 8% to 9% for 2025 >SYK

2025. g. 28. janv. 21:06 UTC

Peļņas

Stryker Sees FY Adj EPS $13.45-Adj EPS $13.70 >SYK

2025. g. 28. janv. 21:05 UTC

Iegādes, apvienošanās, pārņemšana

Stryker: Announces Definitive Agreement for the Sale of U.S. Spinal Implants Business and Plans to Sell Related Intl Business

2025. g. 28. janv. 21:05 UTC

Peļņas

Stryker 4Q Net $500M >SYK

2025. g. 28. janv. 21:05 UTC

Peļņas

Stryker 4Q Adj EPS $4.01 >SYK

2025. g. 28. janv. 21:05 UTC

Peļņas

Stryker 4Q Net $546M >SYK

2025. g. 28. janv. 21:05 UTC

Peļņas

Stryker 4Q Net $500M >SYK

2025. g. 28. janv. 21:05 UTC

Peļņas

Stryker 4Q Sales $6.4B >SYK

2025. g. 28. janv. 21:05 UTC

Peļņas

Stryker 4Q EPS $1.41 >SYK

2025. g. 28. janv. 21:05 UTC

Peļņas

Stryker 4Q Adj EPS $4.01 >SYK

2025. g. 28. janv. 21:05 UTC

Peļņas

Stryker 4Q EPS $1.41 >SYK

2025. g. 28. janv. 21:05 UTC

Peļņas

Stryker 4Q Sales $6.4B >SYK

2025. g. 17. janv. 21:20 UTC

Iegādes, apvienošanās, pārņemšana

Stryker Commences Tender Offer for All Outstanding Shrs of Common Stock of Inari Medical

2025. g. 13. janv. 19:30 UTC

Peļņas

Update: Stryker Had A Good Year Last Year; Here's How It's Looking For 2025 -- IBD

2025. g. 7. janv. 09:58 UTC

Karstas akcijas

Stocks to Watch Tuesday: Nvidia, Uber, Tencent -- WSJ

2025. g. 6. janv. 22:03 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Stryker to Acquire Inari Medical in Deal Valued at $4.9B -- Update

2025. g. 6. janv. 21:49 UTC

Iegādes, apvienošanās, pārņemšana

Inari Medical Catapults -- Again -- After Stryker Confirms $4.9 Billion Deal -- IBD

2025. g. 6. janv. 21:24 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Stryker to Acquire Inari Medical in Deal Valued at $4.9B

2025. g. 6. janv. 21:11 UTC

Iegādes, apvienošanās, pārņemšana

Stryker: Inari's Innovative Pdt Portfolio Is Highly Complementary to Our Neurovascular Business >SYK

2025. g. 6. janv. 21:10 UTC

Iegādes, apvienošanās, pārņemšana

Stryker: Transaction Is Anticipated to Close by the End of the 1Q >SYK

Salīdzinājums

Cenas izmaiņa

Stryker Corp Prognoze

Cenas mērķis

By TipRanks

20.25% augšup

Prognoze 12 mēnešiem

Vidējais 434.15 USD  20.25%

Augstākais 465 USD

Zemākais 390 USD

Pamatojoties uz 21 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Stryker Corp — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

21 ratings

17

Pirkt

4

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

345.99 / 368.365Atbalsts un pretestība

Īstermiņā

Strong Bullish Evidence

Vidējā termiņā

Strong Bearish Evidence

Ilgtermiņā

Strong Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.